{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:46:48Z","timestamp":1792525608265,"version":"4.5.0"},"reference-count":34,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T00:00:00Z","timestamp":1764460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T00:00:00Z","timestamp":1764460800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The phase 3 MANDARA study demonstrated noninferiority of benralizumab versus mepolizumab for remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA). More benralizumab\u2010treated patients achieved complete withdrawal of oral glucocorticoids (OGCs). The objectives of this post hoc analyses are to further elucidate the efficacy of benralizumab and mepolizumab in facilitating reductions in OGCs through investigating timings and sustainability of reducing OGCs as well as the cumulative use of OGCs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults with EGPA requiring \u22657.5\u2009mg\/day OGC with or without immunosuppressive therapy were randomized to benralizumab 30\u2009mg (n\u00a0=\u00a070) or mepolizumab 300\u2009mg (n\u00a0=\u00a070) subcutaneously every 4\u2009weeks for 52\u2009weeks. Investigators tapered OGCs for patients with stable EGPA based on clinical judgment. Reductions in OGC use (to \u22644\u2009mg\/day, by \u226550%, or complete withdrawal) were considered sustained if achieved by week 40 and maintained through week 52.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The 12\u2010month cumulative dose of OGC was approximately 1,800\u2009mg in both groups. At weeks 49 to 52, the median OGC dose was 1.16 (minimum\u2013maximum 0.0\u201316.6) and 3.00 (minimum\u2013maximum 0.0\u201325.7) mg\/day for benralizumab and mepolizumab, respectively. Time to first or sustained OGC reduction to \u22644\u2009mg\/day or by \u226550% and accrued OGC\u2010free duration were similar between groups. More benralizumab\u2010 than mepolizumab\u2010treated patients completely withdrew OGCs (33 of 70 vs 20 of 70; hazard ratio [HR] for the time to the first complete withdrawal 1.84 [95% confidence interval [CI] 1.06\u20133.27]; unstratified log\u2010rank test\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.0291) and sustained complete withdrawal (17 of 70 vs 7 of 70; HR for time to reduction 2.97 [95% CI 1.26\u20137.77]; unstratified log\u2010rank test\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.0268). In both groups, complete OGC withdrawal was similar across patient subgroups, including by antineutrophilic cytoplasmic antibody status and immunosuppressive use.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Targeting the interleukin\u20105 receptor with benralizumab or circulating interleukin\u20105 with mepolizumab are effective OGC\u2010sparing strategies in patients with EGPA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.43398","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T09:02:18Z","timestamp":1758531738000},"page":"695-704","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients With Eosinophilic Granulomatosis With Polyangiitis"],"prefix":"10.1002","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1041-9492","authenticated-orcid":false,"given":"Parameswaran K.","family":"Nair","sequence":"first","affiliation":[{"name":"McMaster University and St. Joseph's Healthcare  Hamilton Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Hellmich","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universit\u00e4t T\u00fcbingen, Kirchheim unter Teck  Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Bourdin","sequence":"additional","affiliation":[{"name":"Department of Respiratory Diseases, University of Montpellier, CHU Montpellier, INSERM, CNRS  Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1712-0637","authenticated-orcid":false,"given":"David R. W.","family":"Jayne","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Cambridge  Cambridge United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Roufosse","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine H\u00f4pital Erasme, Universit\u00e9 Libre de Bruxelles  Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader","family":"Khalidi","sequence":"additional","affiliation":[{"name":"McMaster University and St. Joseph's Healthcare  Hamilton Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"B\u00f6rjesson Sj\u00f6","sequence":"additional","affiliation":[{"name":"Late\u2010stage Respiratory &amp; Immunology, BioPharmaceuticals R&amp;D  AstraZeneca Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Fan","sequence":"additional","affiliation":[{"name":"Late\u2010stage Respiratory &amp; Immunology, BioPharmaceuticals R&amp;D  AstraZeneca Gaithersburg Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"McCrae","sequence":"additional","affiliation":[{"name":"Translational Science &amp; Experimental Medicine, Early Respiratory &amp; Immunology, BioPharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, Maryland (current address: Precision Medicine, Amgen Inc., Thousand Oaks, California)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Necander","sequence":"additional","affiliation":[{"name":"Late\u2010stage Respiratory &amp; Immunology, BioPharmaceuticals R&amp;D  AstraZeneca Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Rodr\u00edguez\u2010Su\u00e1rez","sequence":"additional","affiliation":[{"name":"Translational Science and Experimental Medicine, Early Respiratory &amp; Immunology, BioPharmaceuticals R&amp;D, AstraZeneca, Cambridge, United Kingdom (current address: Novartis, London, United Kingdom)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Shavit","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom (current address: Boehringer Ingelheim, Ingelheim am Rhein, Germany)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Walton","sequence":"additional","affiliation":[{"name":"Late\u2010stage Respiratory &amp; Immunology, BioPharmaceuticals R&amp;D  AstraZeneca Cambridge United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9284-7345","authenticated-orcid":false,"given":"Peter A.","family":"Merkel","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Division of Epidemiology, Department of Biostatistics, Epidemiology, and Informatics University of Pennsylvania  Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Wechsler","sequence":"additional","affiliation":[{"name":"Department of Medicine National Jewish Health  Denver Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,30]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1145257"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41982"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41773"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223764"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/02770903.2017.1353612"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003956"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37721"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208916"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.06.019"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11061089"},{"issue":"9","key":"e_1_2_10_12_1","article-title":"The impact of eosinophilic granulomatosis with polyangiitis on the health\u2010related quality of life of patients and their ability to work: evidence from a real\u2010world survey in clinical practice [abstract]","volume":"76","author":"Spiera R","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2311155"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2024-eular.4920"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.04.004"},{"key":"e_1_2_10_16_1","article-title":"Prescribing information","author":"Fasenra","year":"2017","journal-title":"AstraZeneca"},{"key":"e_1_2_10_17_1","unstructured":"European Medicines Agency.Fasenra. Updated February 27 2025. Accessed November 14 2025.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/fasenra"},{"key":"e_1_2_10_18_1","unstructured":"PR Newswire.FDA approves first drug for eosinophilic granulomatosis with polyangiitis a rare disease formerly known as the Churg\u2010Strauss Syndrome. Published December 12 2017. Accessed November 14 2025.https:\/\/www.prnewswire.com\/news\u2010releases\/fda\u2010approves\u2010first\u2010drug\u2010for\u2010eosinophilic\u2010granulomatosis\u2010with\u2010polyangiitis\u2010a\u2010rare\u2010disease\u2010formerly\u2010known\u2010as\u2010the\u2010churg\u2010strauss\u2010syndrome\u2010300570130.html"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702079"},{"key":"e_1_2_10_20_1","article-title":"Prescribing information","author":"Nucala","year":"2023","journal-title":"GlaxoSmithKline"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00509-2023"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.09.054"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2024.01.006"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00243-6"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224624"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(94)90333-6"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1780037"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2024-eular.5012"},{"issue":"9","key":"e_1_2_10_29_1","article-title":"Characteristics of relapses in patients with eosinophilic granulomatosis with polyangiitis [abstract]","volume":"76","author":"Merkel PA","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S176026"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023386"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613849"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31324-1"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31322-8"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00352-0"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.43398","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/art.43398","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.43398","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T01:58:47Z","timestamp":1773712727000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.43398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,30]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1002\/art.43398"],"URL":"https:\/\/doi.org\/10.1002\/art.43398","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,30]]},"assertion":[{"value":"2025-02-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}